Roche, obesity pill trial
Healthy Returns: How competitive can Roche be in the weight loss drug market?
Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health market with acquisition of Veri.
Roche shares knocked by concern over side effects in obesity pill trial
Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes was linked to an elevated rate of temporary side effects in its initial test phase on humans.
Roche Not Alarmed by Obesity Drug’s Side Effects, R&D Head Says
Roche Holding AG said it isn’t concerned about side effects in a small study of a weight-loss shot, after details about the trial sent shares tumbling on Monday.
Obesity Pill Race Heats Up as Novo, Roche and Terns Share Data
The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, but the comparisons are rife with confounding variables, leaving analysts unsure about where to place their bets.
Roche Shares Slump on Oral Weight-Loss Drug Candidate Side Effects
Roche’s stock fell after new data from an early-stage clinical trial of its closely watched oral weight-loss drug candidate prompted analysts to question the company’s potential to quickly enter a booming obesity market.
Roche Falls as Side Effects Data for Obesity Drug Raises Concern
Shares of Roche Holding AG fell after a poster highlighted side effects in an early-stage study of the Swiss pharmaceutical company’s experimental obesity medicine.
Roche shares drop on side effects result in early-stage obesity pill trial
Shares in Roche fell on Thursday after an early-stage obesity pill candidate that carries high market hopes was linked to a high rate of temporary side effects in its initial test phase on humans. Roche shares were down 4% at the open at 0700 GMT after the company presented late on Wednesday details on the trial.
Roche's Manu Chakravarthy talks weight loss drug trial results
Manu Chakravarthy, Roche, joins 'Fast Money' to talk its weight loss drug trial results. Snap poll after debate reveals state of presidential race between Trump and Harris Save Money On Steak With This Easy Costco Shopping Tip If you always use these 6 phrases,
Roche Obesity Pill Study: What Are the Side Effects?
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world
Roche shares slip on obesity drug trial side effects
Shares of Roche (SIX:RO) fell on Thursday following reports from an early-stage trial of an obesity medication, which showed a high rate of temporary side effects. At 4:44 am (0844 GMT), Roche was trading 4% lower at
Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows
Roche's phase 3 CENTERSTONE study shows Xofluza (baloxavir marboxil) significantly reduces influenza transmission in households, marking a global first for an antiviral.
BioPharma Dive49m
Roche’s Xofluza reduces flu transmission in Phase 3 study
According to the company, the results are the first time an antiviral drug has reduced transmission of a respiratory virus in a global Phase 3 trial.
ENDPOINTS NEWS2d
Roche out­lines com­mer­cial man­u­fac­tur­ing strat­e­gy for GLP-1/GIP as­sets
Roche has already budgeted for future commercial manufacturing builds and established a network of contract manufacturers as ...
Roche's Xofluza Reduces Influenza Transmission In Phase III Study
Xofluza (baloxavir marboxil), an antiviral medication, achieved its primary endpoint in the phase III CENTERSTONE ...
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first ...
STAT6d
FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug
Swiss pharma giant Roche won approval from the Food and Drug Administration on Friday for an injectable version of its blockbuster multiple sclerosis therapy Ocrevus, cutting down the time needed ...
Roche Holding AG: A Cautious Hold Amidst Competition and Pipeline Uncertainties
Stifel Nicolaus analyst Eric Le Berrigaud has maintained their neutral stance on RHHVF stock, giving a Hold rating today. Eric Le ...
Lunit announces partnership with Roche to integrate AI into PD-L1 biomarker testing
"Lunit announces partnership with Roche to integrate AI into PD-L1 biomarker testing" was originally created and published by ...